Cargando…

Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021

IMPORTANCE: Although several cancer drugs receive US Food and Drug Administration (FDA) approval each month, it is unclear how many of these cancer drugs transform the treatment landscape significantly by tumor group. Specifically, it remains unclear how many of these newly approved cancer drugs dis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Benjamin, David J., Xu, Alexander, Lythgoe, Mark P., Prasad, Vinay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924721/ https://www.ncbi.nlm.nih.gov/pubmed/35289858 http://dx.doi.org/10.1001/jamanetworkopen.2022.2265

Ejemplares similares

Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015-2020
por: Haslam, Alyson, et al.
Publicado: (2021)

Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action
por: Olivier, Timothée, et al.
Publicado: (2021)

Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016
por: Ladanie, Aviv, et al.
Publicado: (2020)

Approvals and Timing of New Formulations of Novel Drugs Approved by the US Food and Drug Administration Between 1995 and 2010 and Followed Through 2021
por: Gupta, Ravi, et al.
Publicado: (2022)

Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019
por: Lythgoe, Mark P., et al.
Publicado: (2022)

Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021
por: Vokinger, Kerstin N., et al.
Publicado: (2022)

Use of US Food and Drug Administration Expedited Drug Development and Review Programs by Orphan and Nonorphan Novel Drugs Approved From 2008 to 2021
por: Monge, Andrea N., et al.
Publicado: (2022)

Approvals in 2021: dangling Accelerated Approvals, drug dosing, new approvals and beyond
por: Lemery, Steven, et al.
Publicado: (2022)

National Comprehensive Cancer Network Guideline Recommendations of Cancer Drugs With Accelerated Approval
por: Cliff, Edward R. Scheffer, et al.
Publicado: (2023)

Use of Extrapolation in New Drug Approvals by the US Food and Drug Administration
por: Feldman, Daniel, et al.
Publicado: (2022)

Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration
por: Hutchinson, Nora, et al.
Publicado: (2021)

Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals
por: Lammers, Austin, et al.
Publicado: (2017)

Trends in Ransomware Attacks on US Hospitals, Clinics, and Other Health Care Delivery Organizations, 2016-2021
por: Neprash, Hannah T., et al.
Publicado: (2022)

Leveraging existing opportunities for improved Orphan Drug approval in the EU
por: Edfjäll, Catarina
Publicado: (2012)

Repositioning canakinumab for non-small cell lung cancer—important lessons for drug repurposing in oncology
por: Lythgoe, Mark P., et al.
Publicado: (2022)

Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020
por: Mitra-Majumdar, Mayookha, et al.
Publicado: (2022)

High-risk Therapeutic Devices Approved by the US Food and Drug Administration for Use in Children and Adolescents From 2016 to 2021
por: Pathak, Kavya, et al.
Publicado: (2022)

Comparison of COVID-19 Vaccine Approvals at the US Food and Drug Administration, European Medicines Agency, and Health Canada
por: Lythgoe, Mark P., et al.
Publicado: (2021)

US Food and Drug Administration Approvals of Drugs and Devices Based on Nonrandomized Clinical Trials: A Systematic Review and Meta-analysis
por: Razavi, Marianne, et al.
Publicado: (2019)

Comparison of Drugs Used for Adjuvant and Metastatic Therapy of Colon, Breast, and Non–Small Cell Lung Cancers
por: Parsons, Scott, et al.
Publicado: (2020)

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
por: Cherla, Avi, et al.
Publicado: (2021)

Recent Trends in Medicaid Spending and Use of Drugs With US Food and Drug Administration Accelerated Approval
por: Sachs, Rachel E., et al.
Publicado: (2021)

Consistency and Adequacy of Public and Commercial Health Insurance for US Children, 2016 to 2021
por: Daw, Jamie R., et al.
Publicado: (2023)

Pre‐approval and post‐approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: A comparison with standard approved cancer drugs
por: Bloem, Lourens T., et al.
Publicado: (2022)

Repurposing of existing FDA approved drugs for Neprilysin inhibition: An in-silico study
por: Sankhe, Runali, et al.
Publicado: (2021)

Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration
por: Modi, Natansh D., et al.
Publicado: (2022)

Assessment of Outcomes Associated With the Use of Newly Approved Oncology Drugs in Medicare Beneficiaries
por: Green, Angela K., et al.
Publicado: (2021)

Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020
por: Zhang, Yichen, et al.
Publicado: (2022)

US Food and Drug Administration Accelerated Approval Program for Nononcology Drug Indications Between 1992 and 2018
por: Omae, Kenji, et al.
Publicado: (2022)

Trends and Characteristics of New Drug Approvals in China, 2011–2021
por: Su, Ling, et al.
Publicado: (2022)

Contribution of NIH funding to new drug approvals 2010–2016
por: Galkina Cleary, Ekaterina, et al.
Publicado: (2018)

FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022
por: Rizzo, Carla, et al.
Publicado: (2023)

Chemistry and Pharmacology of Fluorinated Drugs Approved by the FDA (2016–2022)
por: Shabir, Ghulam, et al.
Publicado: (2023)

Quantification of US Food and Drug Administration Premarket Approval Statements for High-Risk Medical Devices With Pediatric Age Indications
por: Lee, Samuel J., et al.
Publicado: (2021)

Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies
por: Tay-Teo, Kiu, et al.
Publicado: (2019)

Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs
por: Miller, Jennifer E., et al.
Publicado: (2021)

FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019
por: Chen, Emerson Y., et al.
Publicado: (2020)

Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017
por: Skydel, Joshua J., et al.
Publicado: (2022)

Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019
por: Dhodapkar, Meera, et al.
Publicado: (2021)

Association of Research and Development Investments With Treatment Costs for New Drugs Approved From 2009 to 2018
por: Wouters, Olivier J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tpitsusbpfhtrf3mp31l6hep8u